Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche’s Esbriet and Boehringer Ingelheim’s Ofev.
A number of growth drivers have emerged within the IPF market over the last five years, namely the acknowledgement of the lucrative IPF therapeutic market by pharmaceutical companies looking to meet the series of clinical unmet needs. These include both larger and smaller biotechnology companies alike. As such, the landscape will continue to evolve and the increasing uptake of current therapies and approval of new products will be the primary drivers of growth over the forecast period.
KEY QUESTIONS ANSWERED
Which unmet needs are limiting the treatment of IPF in the 7MM?
What strategies can the pharmaceutical industry employ to increase treatment rates for IPF? How should these strategies differ across different geographical markets?
What effect will the launch of generics have on the sales of branded agents?
What are the main R&D trends in the IPF market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
What was the impact of the COVID-19 pandemic on the IPF treatment, clinical trial conduct, and looking forward?

Scope

Overview of IPF including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline IPF market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting IPF therapeutics sales in the 7MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest drivers of growth in the global IPF market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.

The main barriers to growth in the IPF market include low diagnostic and treatment rates and the patent expiries of both Ofev and Esbriet in all markets.

The late-stage pipeline products are completely distinct mechanisms of action both from each other and the available marketed therapies.

The most important unmet needs in the IPF market are improved drug safety and efficacy and improvement in patient quality of life.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global IPF therapeutics market from 2019-2029.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Boehringer-Ingelheim
F. Hoffman La Roche
Galapagos NV
Fibrogen
Bristol Myers Squibb’s Celgene
Galecto Biosciences
PharmAkea Therapeutics
Liminal Biosciences

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

2.1 IPF Market to Experience Conservative Growth over the Forecast Period

2.2 Innovative Small Pharma Require Partnerships to Sustain Development

2.3 High Unmet Clinical Needs Remain

2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

4.2.1 GAP Model

4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for IPF (2019-2029)

5.5.1 Diagnosed Incident Cases of IPF

5.5.2 Sex-Specific Diagnosed Incident Cases of IPF

5.5.3 Age-Specific Diagnosed Incident Cases of IPF

5.5.4 Diagnosed Prevalent Cases of IPF

5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF

5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF

5.5.7 Diagnosed Prevalent Cases of IPF by Severity

5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities

5.5.9 Total Prevalent Cases of IPF

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Coronavirus Disease 2019 (COVID-19) Impact

5.6.3 Limitations of Analysis

5.6.4 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Current Treatment Guidelines

6.3 Symptomatic Treatments

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Earlier Diagnosis

7.3 Improved Drug Safety and Efficacy

7.4 Improvement in Patient Quality of Life

7.5 Treatments for Patients with Severe Disease

8 R&D Strategies

8.1 Overview

8.1.1 Corporate Partnerships

8.1.2 Combination Therapy

8.2 Clinical Trial Design

8.2.1 Appropriate Endpoints

8.2.2 Increased Use of Quality of Life Measures

8.2.3 Add-Ons to Standard of Care

8.2.4 Selection of Patient Population

9 Impact of COVID-19 on the IPF Disease Space

9.1 Overview

9.2 Continuity of Care

9.3 Trial Logistics

9.3.1 Recruitment

9.3.2 Trial Conduct in Isolation

9.3.3 Supply Chain

9.4 Long-Term Impact on the Disease Space

10 Pipeline Assessment

10.1 Overview

10.2 Innovative Early-Stage Approaches

11 Pipeline Valuation Analysis

11.1 Clinical Benchmark of Key Pipeline Drugs

11.2 Commercial Benchmark of Key Pipeline Drugs

11.3 Competitive Assessment

11.4 Top-Line 10-Year Forecast

11.4.1 US

11.4.2 5EU

11.4.3 Japan

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Frequently asked questions

Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 in real time.

  • Access a live Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.